# ITGR earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/ITGR) · [Earnings tab](https://www.lopjlb.com/stock/ITGR?tab=earnings)

Updated: 2026-10-26T03:21:25

Quarters analyzed: 8

## Cross-quarter narrative

Across eight earnings calls Integer Holdings moved from a phase of strong top‑line growth and confident margin expansion to a period marked by heightened product‑adoption headwinds and strategic recalibration. Early calls (Q2‑Q4 2024) highlighted 9‑11% sales growth, expanding margins driven by manufacturing excellence, and on‑track integration of InNeuroCo and Pulse acquisitions. Leadership changes began in Q3 2024 with a new COO and continued with a CEO succession announced in Q5 2025. The company maintained high demand visibility through multiyear contracts, yet organic growth slowed in Cardio & Vascular and later faced volatility from hurricane impacts and macro‑economic concerns. From Q5 2025 onward, recurring fears around acquisition integration, FX volatility and new‑product adoption intensified, culminating in a lowered 2025 sales outlook in Q3 2025 and a 3‑4% headwind from three new electrophysiology/neuromodulation products in FY26. Despite short‑term margin pressure, the firm pursued deleveraging, completed the Portable Medical exit, and launched a strategic review in Q1 2026 while reaffirming an above‑market growth target for 2027.

## Latest CallCard · Q1

Integer Q1 sales in-line; cuts 2026 outlook on EP forecast normalization and portfolio risk-adjustment; announces strategic review; reaffirms 2027 above-market growth target.

**Guidance:** lowered — Reported sales guidance lowered to down 1-3% (from prior); organic flat to down 1%; organic ex-3 new products 3-4% (from 4-6%); adjusted EBITDA $375-399M (down 1-7% YoY).

**Tone:** mgmt -0.2 · Q&A pressure 0.6 · divergence 0.2

Management acknowledges near-term headwinds from EP normalization and portfolio risk-adjustments but emphasizes long-term fundamentals and 2027 above-market growth target.

### Demand visibility

Customer POs provide 1-2 quarter visibility; rolling 12-month forecasts shared but subject to adjustment; EP normalization reducing H2 visibility.

Management receives purchase orders with 1-2 quarter visibility and rolling 12-month forecasts from customers. Recent EP forecast reductions primarily affect H2 2026. Further risk-adjustments applied across portfolio due to variability.

### Margins / costs

Q1 adjusted operating margin down 230 bps to 13.9% on lower fixed cost absorption; further margin pressure expected in 2026; aggressive cost actions underway.

Q1 margin contraction driven by lower fixed cost absorption. Full-year adjusted operating income guided down 5-11%. Management taking additional near-term cost actions to mitigate profit impact without compromising 2027 growth. OpEx highly fixed; variable costs managed with volumes.

### Capital allocation

Share repurchases continued ($50M in Q1, $50M in Q4 2025); strategic review initiated; CapEx $95-105M; free cash flow $85-105M; leverage target 2.5-3.5x.

Completed $50M share repurchase in Q1 2026 (~600K shares) and $50M in Q4 2025. Board initiated strategic review to explore value maximization options. CapEx ~5-6% of sales. Year-end net debt target $1.185-1.205B.

### Milestones

- **3 new products headwind** [at_risk]: 3-4% headwind to 2026 reported growth; outlook unchanged
- **2 PFA products previously discussed** [on_track]: Forecast and purchase orders tracking in line; outlook unchanged
- **EP portfolio expansion** [on_track]: Strong portfolio across major players; Q1 EP ex-2 new products above market
- **New product launches H2 2026 and 2027** [on_track]: Launches expected in all growth markets; supports 2027 above-market growth
- **Strategic review** [new]: Board initiated process; no deadline or guaranteed outcome
- **Portable Medical exit** [delivered]: Completed; contributed to inorganic decline
- **CRM&N growth** [on_track]: CRM slightly ahead of expectations in Q1; neuromod headwind from one product
- **Neuromodulation emerging customers PMA products** [on_track]: Expected 15-20% growth over 3-5 years

### Fears / risks

- **EP market normalization**: Rapid PFA adoption created forecasting complexity; customers adjusting production plans as market stabilizes
- **Customer inventory adjustments**: Order pattern variability as customers manage inventory during normalization
- **Further forecast erosion**: Risk-adjusted guidance across portfolio to minimize potential additional reductions
- **Strategic review uncertainty**: No deadline or guaranteed outcome; could distract from execution
- **Inflation and supply chain**: Middle East conflict causing some inflation; supply chain disruption risk deemed minimal but monitored
- **Fixed cost absorption**: Lower volumes pressure margins; OpEx highly fixed limiting flexibility
- **2027 growth dependency**: Above-market growth relies on EP reacceleration and new product launch execution
- **Macro economic uncertainty**: Prolonged conflict or economic uncertainty could affect demand visibility

### Key quotes

> “We now expect reported sales to be in the range of down 1% to 3% compared to the prior year. On an organic basis, we expect sales to be flat to down 1%.”

> “We believe there is a clear view of the market dynamics and needs for various EP products. As a result, certain customers have adjusted their forecast for a few products. We expect the impact of these updates to be short term, primarily”

> “The EP market continues to be a very strong market for us. In fact, in the first quarter, our EP business, excluding the 2 new products, had very strong performance. We believe that our performance in EP in 1Q was above market.”

> “Our Board has a fiduciary responsibility to always make sure that we are maximizing shareholder value. And although we believe that the strategy that we have is we can do that. Given the heightened interest that we've had in recent months,”

> “We are looking to be more aggressive on the cost actions and the disciplined cost management but still ensuring that we're not going to damage the ability to return to market growth and the above market.”

## Quarter one-liners

- **2026 Q1:** Integer Q1 sales in-line; cuts 2026 outlook on EP forecast normalization and portfolio risk-adjustment; announces strategic review; reaffirms 2027 above-market growth target.
- **2025 Q4:** Integer delivered 8% sales growth and 21% EPS increase in FY25, maintained FY26 guidance despite three new‑product headwinds, and reaffirmed confidence in returning to above‑market growth in 2027.
- **2025 Q3:** Integer Q3 2025 beats expectations but lowers 2025 sales outlook $16M on emerging customer forecast cuts; preliminary 2026 organic growth flat to low-single-digit due to 3 new product headwinds (2 EP, 1 neuromodulation), with recovery expected 2H 2026 and above-market growth in 2027; CEO transition 
- **2025 Q2:** Integer posted 11% sales growth and raised its adjusted operating income and EPS outlook while keeping sales guidance, citing strong new‑product ramps, margin expansion and solid demand visibility.
- **2025 Q1:** Integer Holdings reported 7% sales growth, raised EPS outlook, completed two tuck‑in acquisitions and a debt refinancing, and announced a CEO transition to Peyman Kales effective Oct 24 2025.
- **2024 Q4:** Integer Holdings posted 11% organic sales growth in Q4, guided 2025 organic growth 6-8% above market, driven by product development pipeline and tuck-in acquisitions (Precision Coatings, VSI Parylene), while exiting Portable Medical.
- **2024 Q3:** Integer posted strong Q3 2024 results, raised its full‑year profit and EPS outlook, highlighted margin expansion and high demand visibility, announced a new COO and upcoming leadership changes, and noted a 1% organic growth hit from Hurricane Helene.
- **2024 Q2:** Integer posted 9% sales growth, raised its full-year profit outlook, highlighted strong order book and margin expansion, while noting slower organic growth in Cardio & Vascular and maintaining confidence in execution.

## Theme arcs

- **Demand visibility** (stable): High backlog and multiyear contracts consistently cited, but near‑term uncertainty grew with new‑product adoption risk.
- **Margin expansion** (improving): Manufacturing efficiency and expense leverage drove expanding margins, though occasional short‑term pressure noted.
- **Acquisition integration** (improving): Early deliveries of InNeuroCo and Pulse were achieved; later integration risk persisted but remained manageable.
- **Leadership transition** (new): COO promotion in Q3 2024 and CEO succession announced Q5 2025, creating execution risk.
- **New product adoption risk** (deteriorating): Adoption headwinds for two EP and one neuromodulation product emerged Q3 2025 and persisted through Q1 2026.
- **FX volatility** (stable): Currency impacts repeatedly cited, affecting adjusted EPS and net income.
- **Debt leverage and financial flexibility** (improving): Leverage stayed within target range and deleveraging pursued in FY25‑26.
- **Portable Medical exit** (resolved): Exit tracked from Q4 2025 and completed by Q3 2026.
- **Strategic review** (new): Initiated Q1 2026 to assess portfolio amid product headwinds.
- **EP market normalization** (deteriorating): Rapid PFA adoption created forecasting complexity and reduced visibility for H2 2026.

## Guidance path

2024 Q2:raised → 2024 Q3:raised → 2024 Q4:maintained → 2025 Q1:raised → 2025 Q2:raised → 2025 Q3:lowered → 2025 Q4:maintained → 2026 Q1:lowered

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/ITGR`